logo
Plus   Neg
Share
Email

Edwards Lifesciences Backs FY17 View, Sees Higher FY18; To Buy Back $1 Bln Share

Edwards Lifesciences Corp. (EW), a company in patient-focused innovations for structural heart disease and critical care monitoring, Thursday said it reaffirmed

For fiscal 2017, the company still expects adjusted earnings per share of $3.65 to $3.85, and global sales at the high end of $3 billion to $3.4 billion target, representing underlying growth of 10 to 11%.

On average, analysts polled by Thomson Reuters expect earnings of $3.75 per share on sales of $3.39 billion for the year. Analysts' estimates typically exclude special items.

For fiscal 2018, the company expects adjusted earnings per share of $4.10 to $4.30, and global sales of $3.5 to $3.9 billion, representing underlying growth of 9 to 10%.

Analysts expect earnings of $4.15 per share on sales of $3.71 billion for the year.

The company expects 2018 THVT sales of $2.1 to $2.4 billion, representing underlying growth of 11% to 15%.

The company will discuss its strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance during its annual investor conference today in New York City.

Michael Mussallem, chairman and CEO, said, "In 2018, we are projecting strong financial results while we continue to invest aggressively to provide breakthrough therapies for patients in need. During the year, we expect to achieve a number of meaningful clinical milestones that will serve as indicators of our progress in advancing multiple transcatheter mitral and tricuspid programs."

Separately, Edwards Lifesciences announced that its Board of Directors recently authorized a new share repurchase program to acquire up to an additional $1 billion of the company's outstanding common shares.

The company also announced that in November it entered into an accelerated share repurchase agreement to acquire $150 million of Edwards' common stock.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A $716 billion defense policy bill easily cleared the Senate on Monday, although the legislation must still be reconciled with the version previously approved by the House. The Senate voted 85 to 10 in favor of the National Defense Authorization Act, which authorizes U.S. military spending for fiscal 2019. Voip-Pal.com Inc. has filed a lawsuit against Amazon Inc., accusing Alexa's calling and messaging services of infringing its patents. The lawsuit, filed by Voip-Pal in the U.S. District Court in Nevada, accuses Amazon's Alexa calling and messaging system of using Voip-Pal's patented technologies to direct voice/video calls and voice messages to both Amazon subscribers and non-subscribers. Canada is a step closer to becoming the first G-7 nation to legalize marijuana nationwide after the House of Commons voted to allow recreational use. The bill will now go back to the country's Senate, which had already approved a version of the bill. On Monday, the House of Commons voted 205 to 82 in favor of the Bill C-45, known as the Cannabis Act.
Follow RTT